Press Releases

Tel Aviv, Israel— February 7, 2018 – InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced a 1-for-35 reverse split of its common stock, effective as of February 7, 2018.  Beginning on February 8, 2018, the Company’s common stock will trade… Read More

Tel Aviv, Israel— January 31, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System (EPS) was successfully featured once again on a live case transmission at the Leipzig Interventional Course (LINC) 2018 on January 30th. Dr…. Read More

Tel Aviv, Israel— January 30, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System (EPS) was successfully featured in a live case transmission at the Leipzig Interventional Course (LINC) 2018 on January 30th. Dr. Antonio Micari… Read More

Tel Aviv, Israel— January 26, 2018 – InspireMD, Inc.  (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System (EPS) will be featured in two separate live case transmissions at the Leipzig Interventional Course (LINC) 2018 to be held from January 30th… Read More

Tel Aviv, Israel— January 19, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of an independent observational study conducted by Tomoyuki Umemoto, MD and colleagues in the December 2017 issue of the journal EuroIntervention demonstrating the advantage of CGuard™ EPS in… Read More

Tel Aviv, Israel— January 19, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of an independent observational study conducted by Tomoyuki Umemoto, MD and colleagues in the December 2017 issue of the journal EuroIntervention demonstrating the advantage of CGuard™ EPS in… Read More

Conference call to be held at 10AM Eastern today to discuss recent developments, preliminary sales results and proposals for upcoming shareholder meeting   Tel Aviv, Israel— January 10, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary unaudited sales results for the fourth… Read More

Tel Aviv—January 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, January 10th at 10:00 a.m. Eastern Time to discuss recent developments, preliminary unaudited fourth quarter 2017 sales results, and proposals under consideration for… Read More

Tel Aviv, Israel— January 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory approval for the CGuard™ Embolic Prevention System (EPS) in India. The approval was granted by India’s Central Drugs Standard Control Organisation within the Ministry of… Read More

Professor Pierfrancesco Veroux treated a patient with carotid artery disease using CGuard™ EPS Tel Aviv, Israel— December 18, 2017 – InspireMD, Inc.  (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that CGuardTM EPS was once again prominently featured in a live clinical case at an industry… Read More